Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript
Source: SeekingAlpha
2025-11-22 07:23:53 ET
Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns November 17, 2025 12:00 PM EST...
Read the full article on Seeking Alpha
For further details see:
Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript
Dare Bioscience Inc.
NASDAQ: DARE
DARE Trading
0.66% G/L:
$1.53 Last:
13,017 Volume:
$1.54 Open:
DARE Latest News
February 23, 2026 08:00:00 am
Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
February 11, 2026 08:00:00 am
Telehealth Now Available for DARE to PLAY(TM) Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women
DARE Stock Data
$24,148,797
13,603,346
0.17%
11
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
